Answers are grounded in this paper and cite their sources.
Purpose Tarlatamab is approved for 2L+ extensive stage small cell lung cancer (ES-SCLC). In previously published retrospective studies, tarlatamab resulted in inferior survival compared to that observed in the DeLLphi-304 trial. To better understand real world outcomes with tarlatamab, we examined a much larger, multi-institutional dataset. Methods Utilizing the US-based, de-identified Flatiron Health Research Database, patients treated with tarlatamab between 3/2024 and 09/2025 were identified. Baseline characteristics, treatment history, and clinical outcomes were summarized. Median time to treatment discontinuation (mTTD), real-world progression-free survival (mPFS) and overall survival (mOS) from start of tarlatamab were estimated via Kaplan Meier methods. Effects of baseline patient characteristics were estimated via log-rank analysis and Cox regression. Results Of 204 patients identified, 90 (44%) were female. 62 (30%) patients were ECOG PS 0, 86 (42%) were ECOG 1, 48 (24%) were ECOG ≥2. 75 (37%) received tarlatamab in 2L, 64 (32%) in 3L, and 65 (31%) in 4L+. mPFS was 3.8 months(m), mTTD was 2.3m, and mOS was 11.2m. Patient sex, race (Black vs White) and age (<65 vs ≥65yo) were not associated with TTD, PFS, or OS. ECOG PS ≥ 2 compared to ECOG 0-1 was associated with shorter mPFS (2.1 vs 4.5; p=0.004); mTTD (1.6 vs 2.8; p=0.001) and mOS (3.2 vs 13.4; p<0.001). Conclusion In the largest retrospective analysis to date, mTTD, mPFS, and mOS in patients with intact PS (0-1) appeared similar to outcomes reported in DeLLphi-304. By contrast, ECOG PS ≥2 was associated with shorter TTD, PFS, and OS, which may account for inferior real-world outcomes compared to the trial. Line of therapy in our cohort was not associated with outcomes; nor was race, sex or age.
No takes yet. Share an insight, caveat, or question.
Barsouk et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: